1. Home
  2. OCX vs FAAS Comparison

OCX vs FAAS Comparison

Compare OCX & FAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCX
  • FAAS
  • Stock Information
  • Founded
  • OCX 2009
  • FAAS 2021
  • Country
  • OCX United States
  • FAAS Indonesia
  • Employees
  • OCX N/A
  • FAAS N/A
  • Industry
  • OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • FAAS
  • Sector
  • OCX Health Care
  • FAAS
  • Exchange
  • OCX Nasdaq
  • FAAS NYSE
  • Market Cap
  • OCX 35.1M
  • FAAS 29.1M
  • IPO Year
  • OCX N/A
  • FAAS N/A
  • Fundamental
  • Price
  • OCX $2.01
  • FAAS $0.60
  • Analyst Decision
  • OCX Buy
  • FAAS
  • Analyst Count
  • OCX 3
  • FAAS 0
  • Target Price
  • OCX $4.42
  • FAAS N/A
  • AVG Volume (30 Days)
  • OCX 53.0K
  • FAAS 431.5K
  • Earning Date
  • OCX 11-12-2024
  • FAAS 09-17-2024
  • Dividend Yield
  • OCX N/A
  • FAAS N/A
  • EPS Growth
  • OCX N/A
  • FAAS N/A
  • EPS
  • OCX N/A
  • FAAS N/A
  • Revenue
  • OCX $709,000.00
  • FAAS $57,730,593.00
  • Revenue This Year
  • OCX N/A
  • FAAS N/A
  • Revenue Next Year
  • OCX $106.34
  • FAAS N/A
  • P/E Ratio
  • OCX N/A
  • FAAS N/A
  • Revenue Growth
  • OCX N/A
  • FAAS 38.16
  • 52 Week Low
  • OCX $1.92
  • FAAS $0.38
  • 52 Week High
  • OCX $3.48
  • FAAS $12.97
  • Technical
  • Relative Strength Index (RSI)
  • OCX 42.58
  • FAAS 41.84
  • Support Level
  • OCX $1.99
  • FAAS $0.43
  • Resistance Level
  • OCX $2.30
  • FAAS $0.55
  • Average True Range (ATR)
  • OCX 0.12
  • FAAS 0.10
  • MACD
  • OCX 0.02
  • FAAS -0.01
  • Stochastic Oscillator
  • OCX 25.70
  • FAAS 19.95

About OCX Oncocyte Corporation

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.

About FAAS DIGIASIA CORP

DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.

Share on Social Networks: